ARTICLE | Clinical News
Biohaven's acute migraine candidate meets in Phase III
March 26, 2018 9:45 PM UTC
Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) said Monday that rimegepant (formerly BHV-3000) met the co-primary endpoints in a pair of Phase III trials to treat acute migraine. The company plans to submit an NDA to FDA in 2019 for the calcitonin-gene related peptide (CGRP) receptor antagonist.
The 301 and 302 trials compared placebo with once-daily 75 mg oral rimegepant, given without any rescue medication, in 1,084 and 1,072 patients, respectively...